AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DIMERIX LTD

0.325

+0.0051.56%

Volume:469.31K

Turnover:149.11K

Market Cap:195.13M

PE:-11.62

High:0.325

Open:0.315

Low:0.310

Close:0.320

52wk High:0.785

52wk Low:0.310

Shares:600.40M

Float Shares:467.70M

Volume Ratio:0.57

T/O Rate:0.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.028

EPS(LYR):-0.024

ROE:-594.54%

ROA:-58.27%

PB:-116.07

PE(LYR):-13.74

Loading ...

Overview Company News Filings

Dimerix Ltd-Biomarin to Acquire Dimerix US Partner, Amicus Therapeutics

THOMSON REUTERS

Dmx-200 Action3 Phase 3 Trial Completes Recruitment

THOMSON REUTERS

Dimerix Completes Dosing of 286 Adult Patients in Phase Three Kidney Disease Drug Candidate Trial

MT Newswires Live

ASX Penny Stocks To Consider In December 2025

Simply Wall St.

Dimerix Says IDMC Found No Safety Concerns in Phase Three Kidney Disease Trial

MT Newswires Live

Dimerix Ltd-Successful Completion of Planned Idmc Review

THOMSON REUTERS

Dimerix's Potential Interim Results May Potentially Enable Accelerated Approval in the US in 2026, Euroz Hartleys Says

MT Newswires Live

Dimerix to Benefit from Filpari's Approval, But Nothing to Lose from Rejection, Says Euroz Hartleys

MT Newswires Live

3 hot sectors, a handful of stock ideas, and what could come next

Dimerix Says Analysis Results Support Use of Protein in Urine as Endpoint for Kidney Disease Trials; Shares Rise 7%

MT Newswires Live

ASX Penny Stocks Spotlight Dimerix And Two More Hidden Gems

Simply Wall St.

Dimerix's Drug Candidate to Treat Kidney Disease Receives Orphan Drug Designation in Japan

MT Newswires Live

Dimerix Ltd - Dmx-200 Receives Orphan Drug Designation in Japan

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DXB.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.325,"timestamp":1774588320000,"preClose":0.32,"halted":0,"volume":469310,"delay":0,"changeRate":0.015625000000000014,"nameEN":"DIMERIX LTD","floatShares":467696880,"shares":600396776,"eps":-0.027967,"marketStatus":"Market Closed","change":0.005,"latestTime":"03-27 16:12:00 AEDT","open":0.315,"high":0.325,"low":0.31,"amount":149109,"amplitude":0.046875,"askPrice":0.325,"askSize":27293,"bidPrice":0.315,"bidSize":155391,"shortable":3,"etf":0,"ttmEps":-0.027967,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1774825200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.32,"openAndCloseTimeList":[[1774566000000,1774587600000]],"volumeRatio":0.5741920313545273,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"DXB.AU","preClose":0.32,"auctionPrice":0.325,"auctionVolume":3499,"auction":3,"marketStatus":"盘后竞价","timestamp":1774588201341}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":467696880,"roa":"-58.27%","roe":"-594.54%","lyrEps":-0.023645,"volumeRatio":0.5741920313545273,"shares":600396776,"dividePrice":0,"high":0.325,"amplitude":0.046875,"preClose":0.32,"low":0.31,"week52Low":0.31,"pbRate":"-116.07","psRate":"26.31","week52High":0.785,"institutionHeld":0,"latestPrice":0.325,"committee":0.7012,"eps":-0.027967,"divideRate":0,"volume":469310,"delay":0,"ttmEps":-0.027967,"open":0.315,"prevYearClose":0.55,"prevWeekClose":0.325,"prevMonthClose":0.475,"prevQuarterClose":0.55,"fiveDayClose":0.325,"twentyDayClose":0.475,"sixtyDayClose":0.55,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DXB.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2593175233","title":"Dimerix Ltd-Biomarin to Acquire Dimerix US Partner, Amicus Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2593175233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593175233?lang=en_us&edition=fundamental","pubTime":"2025-12-22 06:16","pubTimestamp":1766355415,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251221:nTUEBNHV0W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","DXB.AU","BK7501"],"gpt_icon":0},{"id":"2591182326","title":"Dmx-200 Action3 Phase 3 Trial Completes Recruitment","url":"https://stock-news.laohu8.com/highlight/detail?id=2591182326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591182326?lang=en_us&edition=fundamental","pubTime":"2025-12-15 15:00","pubTimestamp":1765782000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUA3KLRWR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","DXB.AU","BK7508"],"gpt_icon":0},{"id":"2591969743","title":"Dimerix Completes Dosing of 286 Adult Patients in Phase Three Kidney Disease Drug Candidate Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591969743","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591969743?lang=en_us&edition=fundamental","pubTime":"2025-12-15 13:38","pubTimestamp":1765777087,"startTime":"0","endTime":"0","summary":"Dimerix  said that the ACTION3 phase three trial of its DMX-200 drug candidate in patients with focal segmental glomerulosclerosis completed the recruitment and dosing of 286 adult patients, according to a Monday Australian bourse filing.The trial is exploring the efficacy and safety of DMX-200 in focal segmental glomerulosclerosis patients when dosed in combination with standard-of-care angiotensin II receptor blocker over two years. It is designed to show evidence of proteinuria reduction and kidney function during the trial, aimed at generating sufficient evidence to support marketing approval.The trial opened 219 sites for recruitment across 21 countries, including the US, Europe, the UK, Japan, China, Hong Kong, Taiwan, Malaysia, Australia, and New Zealand.Of the 286 adult patients dosed in the trial, 69 completed the full two-year treatment period, and of those, 65 entered voluntarily into the open-label extension study, representing a 94% uptake.Dimerix and its US partner, Amicu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","DXB.AU","BK7501"],"gpt_icon":0},{"id":"2590422573","title":"ASX Penny Stocks To Consider In December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590422573","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590422573?lang=en_us&edition=fundamental","pubTime":"2025-12-12 10:05","pubTimestamp":1765505127,"startTime":"0","endTime":"0","summary":"As the Australian market shows signs of a potential rally to close out the year, investors are eyeing opportunities that extend beyond the major indices. Penny stocks, often associated with smaller or newer companies, continue to attract attention for their potential growth and value propositions. Despite being considered an outdated term by some, these stocks remain relevant as they can offer unique opportunities for those looking to explore under-the-radar investments with strong financial...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nuz/neurizon-therapeutics-shares/news/asx-penny-stocks-to-consider-in-december-2025-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nuz/neurizon-therapeutics-shares/news/asx-penny-stocks-to-consider-in-december-2025-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MLX.AU","BK7095","BK7045","BK7012","BK7506","DSK.AU","DXB.AU","BK7143","VRS.AU","BK7077","NUZ.AU","WAF.AU","BK7048","BK7132","BK7096","BK7055","SSM.AU","BK7104","BK7501","BK7067","MTO.AU","BK7128","GWA.AU","EDU.AU","BK7507","BK7508","BK7111","EZZ.AU","AAL.AU","BK7050","IGL.AU"],"gpt_icon":0},{"id":"2584999337","title":"Dimerix Says IDMC Found No Safety Concerns in Phase Three Kidney Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2584999337","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584999337?lang=en_us&edition=fundamental","pubTime":"2025-11-19 11:09","pubTimestamp":1763521785,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) said the Independent Data Monitoring Committee (IDMC) completed a seventh review of the Action3 phase three clinical trial safety data, raising no safety concerns and recommending th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","DXB.AU","BK7501"],"gpt_icon":0},{"id":"2584969973","title":"Dimerix Ltd-Successful Completion of Planned Idmc Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2584969973","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584969973?lang=en_us&edition=fundamental","pubTime":"2025-11-19 06:05","pubTimestamp":1763503547,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUEMLLG1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7501","DXB.AU"],"gpt_icon":0},{"id":"2582353818","title":"Dimerix's Potential Interim Results May Potentially Enable Accelerated Approval in the US in 2026, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2582353818","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582353818?lang=en_us&edition=fundamental","pubTime":"2025-11-11 15:19","pubTimestamp":1762845598,"startTime":"0","endTime":"0","summary":"Dimerix  is approaching key catalysts, including potential interim results, which could potentially enable a faster approval in the US in 2026 and first sales immediately thereafter, according to a Sunday note by Euroz Hartleys.Its interim analysis, expected between late 2025 and early 2026, will determine whether its drug candidate demonstrates efficacy at this point in the trial. It will only proceed if the US Food and Drug Administration  agrees to the interim analysis, the firm is satisfied with the FDA's terms, a powering analysis supports it, and the trial is fully recruited.A blinded statistical power analysis, expected in the December quarter, will verify if Dimerix's trial has adequate statistical power for the confirmatory endpoint, confirming enough patients have been enrolled to detect a meaningful effect at study completion.The investment firm maintained its speculative buy recommendation on Dimerix and its AU$1.68 per share price target.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7067","BK7508","DXB.AU"],"gpt_icon":0},{"id":"2581076953","title":"Dimerix to Benefit from Filpari's Approval, But Nothing to Lose from Rejection, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2581076953","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581076953?lang=en_us&edition=fundamental","pubTime":"2025-11-07 15:02","pubTimestamp":1762498924,"startTime":"0","endTime":"0","summary":"If Dimerix's  US peer Travere's drug Filspari is approved by the US Food and Drug Administration, it would likely be positive for Dimerix, but the consequences would be neutral if rejected, said Euroz Hartleys in a Friday note.The research firm believes that the Filspari launch would raise awareness of focal segmental glomerulosclerosis , improve diagnosis, and establish insurance support for rare kidney disease treatments, and as doctors are expected to use Dimirex's DMX-200 together with Filspari, it could help accelerate acceptance of the medication.If the US FDA rejects Filspari, the effect would likely be neutral for Dimerix, the note added.Euroz Hartleys said that Travere's setback would stem from its trial design, not the medical need. Dimerix's own placebo-controlled study with clear goals follows a stronger regulatory path, keeping its outlook intact.Euroz Hartleys has maintained its speculative buy rating on Dimerix with a price target of AU$1.68.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","DXB.AU","BK7501","BK7508","FSGS"],"gpt_icon":0},{"id":"2575416222","title":"3 hot sectors, a handful of stock ideas, and what could come next","url":"https://stock-news.laohu8.com/highlight/detail?id=2575416222","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575416222?lang=en_us&edition=fundamental","pubTime":"2025-10-15 04:00","pubTimestamp":1760472030,"startTime":"0","endTime":"0","summary":"There have been three dominant sector winners in the last 12 months – AI, gold and defence. These should hardly come as a surprise.There are queues down Martin Place to purchase bullion. Geopolitical risks have heightened and, on the back of a US push, most economies are stepping up their defence spending. And AI hardly needs an explanation as it continues its game-changing growth.Conversely, it’s been a hard year for healthcare, which has been hit by the US tariff on pharmaceuticals, along with vaccine scepticism, and pricing pressures.There’s also been plenty of good economic news out of the US to bolster markets – inflation appears steady, jobs numbers have held up for the most part, and the rate-cutting cycle is still underway to support consumer spending. The story has been mostly similar in Australia – even with a surprise jump in the last inflation print.Only last week, the S&P500 reached 6,764.66 while the S&P/ASX 200 hit an all-time high of 9054.50 back in August. It wasn’t th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/3-hot-sectors-a-handful-of-stock-ideas-and-what-could-come-next","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/3-hot-sectors-a-handful-of-stock-ideas-and-what-could-come-next","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["EOL.AU","BK4543","BK7115","BK4608","BK7094","IE00BZ9MQY76.HKD","NUTX","BK4539","IE00B19Z9P08.USD","BK7506","CRWV","DUG.AU","LU2087625088.SGD","AMI.AU","AYA.AU","TUA.AU","PPE.AU","BK4129","DXB.AU","BK7016","BK4023","LU0353189680.USD","SXE.AU","BK7501","XJO.AU","APE.AU","BK7057","BBN.AU","BK4185","BK4196","BK7143","LU0097036916.USD","AI","LRV.AU","UNI.AU","BK7067","DRO.AU","IE00B19Z9Z06.USD","BK4588","IE00B894F039.SGD","BK4167","MLX.AU","SKS.AU","XKO.AU","APP","FIX","XAO.AU","BK4551","BK7021","BK7023"],"gpt_icon":1},{"id":"2573151719","title":"Dimerix Says Analysis Results Support Use of Protein in Urine as Endpoint for Kidney Disease Trials; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2573151719","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573151719?lang=en_us&edition=fundamental","pubTime":"2025-10-08 10:48","pubTimestamp":1759891712,"startTime":"0","endTime":"0","summary":"Dimerix  said the results of an analysis by Parasol are consistent with the analysis conducted last year that supported the use of proteinuria as a clinical trial endpoint for focal segmental glomerulosclerosis, a kidney disease, according to a Wednesday filing with the Australian bourse.The company said the results cannot be disclosed as they are subject to commercial-in-confidence restrictions.The company, along with its US partner Amicus Therapeutics, intends to seek feedback from the US Food and Drug Administration on the new findings in the coming months, the filing said.Shares of the company rose 7% in recent Wednesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7067","BK7508","DXB.AU"],"gpt_icon":0},{"id":"2573264599","title":"ASX Penny Stocks Spotlight Dimerix And Two More Hidden Gems","url":"https://stock-news.laohu8.com/highlight/detail?id=2573264599","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573264599?lang=en_us&edition=fundamental","pubTime":"2025-10-06 03:02","pubTimestamp":1759690922,"startTime":"0","endTime":"0","summary":"Australian shares are showing signs of consolidation after a recent bullish surge, with the ASX 200 futures indicating a slight decline. Amid such market dynamics, investors often seek opportunities in lesser-known areas like penny stocks, which can still offer growth potential despite their niche status. These smaller or newer companies may present surprising value and stability, making them worth exploring for those interested in diversifying their portfolios.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-dxb/dimerix-shares/news/asx-penny-stocks-spotlight-dimerix-and-two-more-hidden-gems","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-dxb/dimerix-shares/news/asx-penny-stocks-spotlight-dimerix-and-two-more-hidden-gems","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7007","BK7104","BK7048","DSK.AU","AAL.AU","BK7061","DXB.AU","BK7143","BK7162","BK7077","BK7128","BK7045","BK7067","PPS.AU","BK7050","SSM.AU","SOM.AU","WAF.AU","IGL.AU","BK7016","BK7055","BK7062","XAO.AU","BK7506","EZZ.AU","BK7508","BK7501","BK7005","CUP.AU","XKO.AU","BK7503","PPL.AU","XJO.AU","MTO.AU"],"gpt_icon":0},{"id":"2571336480","title":"Dimerix's Drug Candidate to Treat Kidney Disease Receives Orphan Drug Designation in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2571336480","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571336480?lang=en_us&edition=fundamental","pubTime":"2025-09-30 07:49","pubTimestamp":1759189755,"startTime":"0","endTime":"0","summary":"Dimerix  said its drug candidate, DMX-200, for the treatment of focal segmental glomerulosclerosis , a serious and rare disease that attacks the kidney, has received Orphan Drug designation in Japan, according to a Tuesday filing with the Australian bourse.Japanese partner FUSO Pharmaceutical Industries has exclusive rights to develop, register, and commercialize DMX-200 to treat FSGS in the Japanese market.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","FSGS","BK7508","DXB.AU","BK7067"],"gpt_icon":0},{"id":"2571636603","title":"Dimerix Ltd - Dmx-200 Receives Orphan Drug Designation in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2571636603","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571636603?lang=en_us&edition=fundamental","pubTime":"2025-09-30 06:37","pubTimestamp":1759185439,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0GN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","DXB.AU","BK7501"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":33,"code":"91000000","status":"200"}]}}